Altana Pharma Ag

Byk Gulden Lomberg Chemische Fabrik Gmbh

Byk Gulden Lomberg Chemische Fabrik Gesellschaft MIT Beschrankter Haftung

Takeda Gmbh

Katairo Gmbh

Jörg Senn-Bilfinger

Wilm Buhr

Gerhard Grundler

Bernhard Kohl

Peter Jan Zimmermann

Georg Rainer

Peter Jan Zimmerman

Michael W Burnet

Guido Hanauer

Ernst Sturm

Ulrich Thibaut

Ulrich Schraermeyer

Wijnand Faber

Jan Koek

Ton Vries

Michael Burnet

A method for selecting a compound or a composition suitable for treating lipofuscin associated diseases in a patient, the method including the steps of determining a reactivity factor, determining a targeting factor that allows an uptake into a cell and a provides a targeting of lipofuscin, and selecting a compound or a composition or combining compounds to obtain a compound or composition that comprises a reactivity factor and an targeting factor.

Methods for the determination of compounds or compositions for the treatment of lipofuscin related diseases and compounds or compositions

The compound (7R,8R,9R)-2,3-Dimethyl-8-hydroxy-7-(2-methoxyethoxy)-9-phenyl-7,8,9,10-tetrahydro-imidazo-[1,2-h] [1,7] naphthyridine inhibits the secretion of gastric acid.

Tetrahydropyridoethers

The present invention relates to 8-substituted imidazopyridines of a certain formula (1) in which the substitutents and symbols have the meanings indicated in the description. The compounds have gastric secretion inhibiting and excellent gastric and intestinal protective action properties.

8-Substituted imidazopyridines

The invention relates to compounds of the formula (1) where the substituents and symbols are as defined in the description. The compounds are valuable intermediates for preparing active pharmaceutical ingredients.

Tricyclic n-acyl compounds

The invention provides compounds of the formula (I), in which the substituents and symbols are as defined in the description. The compounds inhibit the secretion of gastric acid. 

Tricyclic imidazopyridines

Compounds of formula 1, in which the substituents have the meanings mentioned in the description are suitable for the prevention and treatment of gastrointestinal diseases. 

Prodrugs of imidazopyridine derivatives

The invention relates to imidazopyridines of a certain formula 1, in which the substituents and symbols have the meanings indicated in the description. The compounds have gastric secretion-inhibiting properties.

Polysubstituted imidazopyridines as gastric secretion inhibitors

Compounds of formula (1) in which the substituents have the meanings mentioned in the description, are suitable for the prevention and treatment of gastrointestinal diseases.

This invention is drawn to a process for the production of (R,R)-phenylisoserine or a 1&#x2013;4C-alkyl ester thereof.

Process for the production of 3-phenylisoserine

Compounds of the formula (I), in which the substituents have the meanings mentioned in the description, are suitable for the prevention and treatment of gastrointestinal diseases.

Pyrano[2,3-C]imidazo[-1,2-A]pyridine derivatives for the treatment of gastrointestinal disorders

The invention relates to compounds of Formula (1), in which the substituents and symbols have the meanings indicated in the description. The compounds are valuable intermediates for the preparation of pharmaceutical active compounds.

Tricyclic epoxides

Compounds of the formula 1in which the substituents have the meanings mentioned in the description are suitable for the prevention and treatment of gastrointestinal diseases.

Growing community of inventors

Constance, Germany

Jörg Senn-Bilfinger